Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Wave Life Sciences, Inc.WVE · Entity 4976 | See Remarks | February 26, 2026 | February 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Wave Life Sciences, Inc.
Report date February 26, 2026 · Filed February 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 61,867 |
Ending reported balance
After 2026-02-26 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-02-26 · Exercise / conversion · Acquired 17,900 · Balance 79,767 F1: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Row 2 · 2026-02-26 · Sale · Disposed 17,900 · Balance 61,867 F1: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. F4: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $15.00 to $15.10 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Row 3 · 2026-02-26 · Exercise / conversion · Acquired 15,294 · Balance 77,161 F1: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Row 4 · 2026-02-26 · Sale · Disposed 15,294 · Balance 61,867 F1: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.87 · Expires 2034-02-05 | Direct | 143,200 |
Reported balance
After 2026-02-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-26 · Exercise / conversion · Disposed 17,900 · Balance 143,200 F2: The option vests as to 25% of the shares on February 5, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until February 5, 2028. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.75 · Expires 2033-02-17 | Direct | 61,175 |
Reported balance
After 2026-02-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-26 · Exercise / conversion · Disposed 15,294 · Balance 61,175 F3: The option vests as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025.
F2: The option vests as to 25% of the shares on February 5, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until February 5, 2028.
F3: The option vests as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027.
F4: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $15.00 to $15.10 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2026 Filed Feb 27, 2026 21:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 15,294 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001193125-26-083712 · ownership.xml · derivative · entry 6 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,175 Underlying: Ordinary Shares · 15,294 shares Expires 2033-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 17,900 | $0.00 Strike: $3.87 | $0.00 |
DisclosureSEC source: 0001193125-26-083712 · ownership.xml · derivative · entry 5 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,200 Underlying: Ordinary Shares · 17,900 shares Expires 2034-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests as to 25% of the shares on February 5, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until February 5, 2028. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 15,294 | $15.00 | $229,410.00 |
DisclosureSEC source: 0001193125-26-083712 · ownership.xml · nonDerivative · entry 4 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,867 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 15,294 | $4.75 | $72,646.50 |
DisclosureSEC source: 0001193125-26-083712 · ownership.xml · nonDerivative · entry 3 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,161 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 17,900 | $15.09 | $270,182.60 |
DisclosureSEC source: 0001193125-26-083712 · ownership.xml · nonDerivative · entry 2 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,867 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. F4 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $15.00 to $15.10 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 17,900 | $3.87 | $69,273.00 |
DisclosureSEC source: 0001193125-26-083712 · ownership.xml · nonDerivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:01 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 1,883 | $13.45 | $25,326.35 |
DisclosureSEC source: 0001193125-26-047319 · ownership.xml · nonDerivative · entry 2 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,867 F2 · kind: On February 9, 2026, the reporting person sold 1,883 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations. Read SEC document |
| February 05, 2026 Filed Feb 11, 2026 21:01 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 232,500 | $0.00 Strike: $12.75 | $0.00 |
DisclosureSEC source: 0001193125-26-047319 · ownership.xml · derivative · entry 3 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,500 Underlying: Ordinary Shares · 232,500 shares Expires 2036-02-05 F3 · derivative.exercise_date: The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030. Read SEC document |
| February 05, 2026 Filed Feb 11, 2026 21:01 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 38,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-047319 · ownership.xml · nonDerivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,750 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 9,375 | $0.00 Strike: $3.14 | $0.00 |
DisclosureSEC source: 0001193125-26-005195 · ownership.xml · derivative · entry 4 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,375 shares Expires 2032-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These share options are fully vested. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 1,295 | $16.70 | $21,626.50 |
DisclosureSEC source: 0001193125-26-005195 · ownership.xml · nonDerivative · entry 3 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. F4 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $16.61 to $16.79 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 8,080 | $15.92 | $128,633.60 |
DisclosureSEC source: 0001193125-26-005195 · ownership.xml · nonDerivative · entry 2 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,295 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $15.56 to $16.54 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:30 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 9,375 | $3.14 | $29,437.50 |
DisclosureSEC source: 0001193125-26-005195 · ownership.xml · nonDerivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001193125-25-314737 · ownership.xml · derivative · entry 23 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 22,500 shares Expires 2023-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The share option represented a right to purchase a total of 150,000 ordinary shares that vest as to 25% of the shares on January 1, 2023 and vests as to an additional 6.25% of the shares quarterly thereafter until January 1, 2026. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $10.48 | $0.00 |
DisclosureSEC source: 0001193125-25-314737 · ownership.xml · derivative · entry 22 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 50,000 shares Expires 2031-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: These share options are fully vested. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 168,231 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001193125-25-314737 · ownership.xml · derivative · entry 21 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,469 Underlying: Ordinary Shares · 168,231 shares Expires 2033-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The share option represented a right to purchase a total of 244,700 ordinary shares that vest as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 125,300 | $0.00 Strike: $3.87 | $0.00 |
DisclosureSEC source: 0001193125-25-314737 · ownership.xml · derivative · entry 20 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,100 Underlying: Ordinary Shares · 125,300 shares Expires 2034-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The share option represented a right to purchase a total of 286,400 ordinary shares that vest as to 25% of the shares on February 5, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until February 5, 2028. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $3.14 | $0.00 |
DisclosureSEC source: 0001193125-25-314737 · ownership.xml · derivative · entry 19 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,375 Underlying: Ordinary Shares · 75,000 shares Expires 2032-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The share option represented a right to purchase a total of 150,000 ordinary shares that vest as to 25% of the shares on January 1, 2023 and vests as to an additional 6.25% of the shares quarterly thereafter until January 1, 2026. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 22,500 | $14.08 | $316,800.00 |
DisclosureSEC source: 0001193125-25-314737 · ownership.xml · nonDerivative · entry 18 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 22,500 | $2.83 | $63,675.00 |
DisclosureSEC source: 0001193125-25-314737 · ownership.xml · nonDerivative · entry 17 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 50,000 | $16.00 | $800,000.00 |
DisclosureSEC source: 0001193125-25-314737 · ownership.xml · nonDerivative · entry 16 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 50,000 | $10.48 | $524,000.00 |
DisclosureSEC source: 0001193125-25-314737 · ownership.xml · nonDerivative · entry 15 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 122,349 | $14.20 | $1,736,744.06 |
DisclosureSEC source: 0001193125-25-314737 · ownership.xml · nonDerivative · entry 14 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. F6 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.08 to $15.00 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 122,349 | $4.75 | $581,157.75 |
DisclosureSEC source: 0001193125-25-314737 · ownership.xml · nonDerivative · entry 13 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 147,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 17,900 | $15.00 | $268,500.00 |
DisclosureSEC source: 0001193125-25-314737 · ownership.xml · nonDerivative · entry 12 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 17,900 | $3.87 | $69,273.00 |
DisclosureSEC source: 0001193125-25-314737 · ownership.xml · nonDerivative · entry 11 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 37,500 | $14.08 | $528,000.00 |
DisclosureSEC source: 0001193125-25-314737 · ownership.xml · nonDerivative · entry 10 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 37,500 | $3.14 | $117,750.00 |
DisclosureSEC source: 0001193125-25-314737 · ownership.xml · nonDerivative · entry 9 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 9,375 | $15.00 | $140,625.00 |
DisclosureSEC source: 0001193125-25-314737 · ownership.xml · nonDerivative · entry 8 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 9,375 | $3.14 | $29,437.50 |
DisclosureSEC source: 0001193125-25-314737 · ownership.xml · nonDerivative · entry 7 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 45,882 | $14.50 | $665,289.00 |
DisclosureSEC source: 0001193125-25-314737 · ownership.xml · nonDerivative · entry 6 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 45,882 | $4.75 | $217,939.50 |
DisclosureSEC source: 0001193125-25-314737 · ownership.xml · nonDerivative · entry 5 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 107,400 | $14.56 | $1,563,314.40 |
DisclosureSEC source: 0001193125-25-314737 · ownership.xml · nonDerivative · entry 4 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. F4 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.50 to $14.78 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 107,400 | $3.87 | $415,638.00 |
DisclosureSEC source: 0001193125-25-314737 · ownership.xml · nonDerivative · entry 3 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 28,125 | $14.50 | $407,812.50 |
DisclosureSEC source: 0001193125-25-314737 · ownership.xml · nonDerivative · entry 2 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 28,125 | $3.14 | $88,312.50 |
DisclosureSEC source: 0001193125-25-314737 · ownership.xml · nonDerivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 151,000 | $0.00 Strike: $11.74 | $0.00 |
DisclosureSEC source: 0000950170-25-015680 · ownership.xml · derivative · entry 2 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,000 Underlying: Ordinary Shares · 151,000 shares Expires 2035-02-04 F2 · derivative.exercise_date: The option vests as to 25% of the shares on February 8, 2026, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2029. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-015680 · ownership.xml · nonDerivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2026 through February 8, 2029. Read SEC document |
| November 08, 2024 Filed Nov 13, 2024 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0000950170-24-126622 · ownership.xml · derivative · entry 3 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 36,000 shares Expires 2030-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The share options that were exercised in this reportable transaction were fully vested. Read SEC document |
| November 08, 2024 Filed Nov 13, 2024 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 36,000 | $16.00 | $576,000.00 |
DisclosureSEC source: 0000950170-24-126622 · ownership.xml · nonDerivative · entry 2 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023. Read SEC document |
| November 08, 2024 Filed Nov 13, 2024 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 36,000 | $8.17 | $294,120.00 |
DisclosureSEC source: 0000950170-24-126622 · ownership.xml · nonDerivative · entry 1 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0000950170-24-115726 · ownership.xml · derivative · entry 10 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,500 Underlying: Ordinary Shares · 22,500 shares Expires 2032-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The share options that were exercised in this reportable transaction were fully vested. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 65,625 | $0.00 Strike: $3.14 | $0.00 |
DisclosureSEC source: 0000950170-24-115726 · ownership.xml · derivative · entry 9 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,375 Underlying: Ordinary Shares · 65,625 shares Expires 2032-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The share option represented the right to purchase a total of 150,000 ordinary shares, 25% of which became exercisable on January 1, 2023, and the remaining shares vest as to an additional 6.25% quarterly thereafter until January 1, 2026. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 40,997 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000950170-24-115726 · ownership.xml · derivative · entry 8 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 40,997 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The share options that were exercised in this reportable transaction were fully vested. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 22,500 | $13.50 | $303,750.00 |
DisclosureSEC source: 0000950170-24-115726 · ownership.xml · nonDerivative · entry 7 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 22,500 | $2.83 | $63,675.00 |
DisclosureSEC source: 0000950170-24-115726 · ownership.xml · nonDerivative · entry 6 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 65,625 | $13.75 | $902,343.75 |
DisclosureSEC source: 0000950170-24-115726 · ownership.xml · nonDerivative · entry 5 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 65,625 | $3.14 | $206,062.50 |
DisclosureSEC source: 0000950170-24-115726 · ownership.xml · nonDerivative · entry 4 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 40,997 | $13.00 | $532,961.00 |
DisclosureSEC source: 0000950170-24-115726 · ownership.xml · nonDerivative · entry 3 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 40,997 | $2.48 | $101,672.56 |
DisclosureSEC source: 0000950170-24-115726 · ownership.xml · nonDerivative · entry 2 Francis Chris · CIK 0001657709 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.